Cardiovascular Research (2009) 84, 341–342 Editorial doi:10.1093/cvr/cvp339 Endocannabinoid signalling as an anti-inﬂammatory therapeutic target in atherosclerosis: does it work? Stephan Immenschuh Institute for Transfusion Medicine, Hanover Medical School, Carl-Neuberg-Str. 1, 30625 Hanover, Germany Online publish-ahead-of-print 9 October 2009 This editorial refers to ‘CB1 and CB2 cannabinoid recep- development and progression of atherosclerosis, and Han tors differentially regulate the production of reactive et al. show that cannabinoid receptor expression on these oxygen species by macrophages’ by K.H. Han et al., cells is regulated in a species-speciﬁc manner. Expression pp. 378–386, this issue. of CB1 and CB2 receptors in mouse and human shows a dis- tinct pattern of regulation in response to pro-inﬂammatory The endocannabinoid system is a physiological signalling and pro-atherogenic stimuli that is dependent on the network that has attracted major attention in recent years degree of differentiation of monocytic cells. Importantly, because of its therapeutic potential for the treatment of the differential expression of CB1 and CB2 receptors on various pathological conditions, including cardiovascular mononuclear cells is functionally signiﬁcant. The ratio of disease. More speciﬁcally, targeted modulation of the CB1:CB2 receptor expression regulates the inﬂammatory major receptors of this system, the G-protein-coupled can- activity of these cells and
Cardiovascular Research – Oxford University Press
Published: Dec 1, 2009
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera